Diligent Investors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Diligent Investors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,710	Closed	-$218K	–	370
2026 Q1	$218K	Buy	1,710 +10	+0.6%	+$1.25K	0.05%	328
2025 Q4	$207K	Sell	1,700 -1,000	-37%	-$115K	0.05%	326
2025 Q3	$271K	Hold	2,700	–	–	0.07%	274
2025 Q2	$224K	Hold	2,700	–	–	0.05%	310
2025 Q1	$219K	Hold	2,700	–	–	0.05%	335
2024 Q4	$243K	Hold	2,700	–	–	0.06%	319
2024 Q3	$267K	Hold	2,700	–	–	0.06%	284
2024 Q2	$250K	Hold	2,700	–	–	0.06%	279
2024 Q1	$256K	Sell	2,700 -318	-11%	-$29.5K	0.06%	276
2023 Q4	$269K	Hold	3,018	–	–	0.07%	256
2023 Q3	$220K	Hold	3,018	–	–	0.07%	266
2023 Q2	$251K	Hold	3,018	–	–	0.07%	238
2023 Q1	$230K	Hold	3,018	–	–	0.07%	240
2022 Q4	$250K	Hold	3,018	–	–	0.08%	221
2022 Q3	$239K	Hold	3,018	–	–	0.09%	210
2022 Q2	$224K	Sell	3,018 -125	-4%	-$9.38K	0.08%	223
2022 Q1	$283K	Buy	+3,143	New	+$290K	0.08%	214

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Diligent Investors's XBI Position: Q2 2026 in Review

Diligent Investors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 1,710 shares — an estimated $218K sold.

Diligent Investors first reported a position in XBI in Q1 2022 and held it in 17 quarters. The position peaked at $283K in Q1 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Diligent Investors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
Diligent Investors sold 1,710 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $218K.
Diligent Investors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 17 quarters.
Diligent Investors's State Street SPDR S&P Biotech ETF position peaked at $283K in Q1 2022.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Diligent Investors's 13F filing for Q2 2026, filed 24 Jul 2026.